Pfizer (PFE)
(Delayed Data from NYSE)
$29.97 USD
+0.26 (0.88%)
Updated Jul 19, 2024 04:02 PM ET
After-Market: $29.98 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PFE 29.97 +0.26(0.88%)
Will PFE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PFE
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
4 Large Drug Stocks to Watch as Innovation, M&A Pick Up
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Other News for PFE
Kamala Harris' potential impact on health care stocks
Ex-Dividend Date Nearing for These 10 Stocks – Week of July 22, 2024
Here are Big Pharma’s leading blockbuster makers
Dividend Champion, Contender, And Challenger Highlights: Week Of July 21
See Which Of The Latest 13F Filers Holds Pfizer